m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00060
 [1]
m6A modification ADAR1 ADAR1 YTHDF1 : m6A sites Direct Enhancement RNA modification TNKS TNKS ADAR1 Methylation : modification sites
m6A Modification:
m6A Regulator YTH domain-containing family protein 1 (YTHDF1) READER
 Regulator Info 
m6A Target Interferon-inducible protein 4 (ADAR1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> Adenosine-to-Inosine editing (A-to-I)
Epigenetic Regulator Interferon-inducible protein 4 (ADAR1) WRITER View Details
Regulated Target Tankyrase (TNKS) View Details
Crosstalk Relationship m6A  →  A-to-I Enhancement
Crosstalk Mechanism m6A modification directly impacts RNA modification through modulating the expression level of RNA modification regulator
Crosstalk Summary The A-to-I RNA editing activity of Interferon-inducible protein 4 (ADAR1) plays important roles in the YTHDF1-dependent IFN responses. Therefore, m6A and YTHDF1 affect innate immune responses through modulating the ADAR1-mediated A-to-I RNA editing of mRNA (Tankyrase (TNKS); EIF2AK2 and PSMB2).
Responsed Drug PMID27841036-Compound-37
 Drug Info 
In-vitro Model
 A-172 Glioblastoma Homo sapiens CVCL_0131
LN-229 Glioblastoma Homo sapiens CVCL_0393
Vero Normal Chlorocebus sabaeus CVCL_0059
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Tankyrase (TNKS) 2 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name PMID27841036-Compound-37 Phase 2 [2]
Synonyms
2X-121
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 50 nM
External Link
CID: 135565981
TTD: D0F5TD
 Compound Name Stenoparib Phase 2 [3]
MOA Inhibitor
External Link
TTD: DP48WE
References
Ref 1 N6-methyladenosine promotes induction of ADAR1-mediated A-to-I RNA editing to suppress aberrant antiviral innate immune responses. PLoS Biol. 2021 Jul 29;19(7):e3001292. doi: 10.1371/journal.pbio.3001292. eCollection 2021 Jul.
Ref 2 PARP inhibitors as antitumor agents: a patent update (2013-2015). Expert Opin Ther Pat. 2017 Mar;27(3):363-382. doi: 10.1080/13543776.2017.1259413. Epub 2016 Nov 21.
Ref 3 Clinical pipeline report, company report or official report of Allarity Therapeutics.